Last reviewed · How we verify
Albumin-bound docetaxel
Albumin-bound docetaxel is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Albumin-bound docetaxel |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study (PHASE2)
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (PHASE3)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albumin-bound docetaxel CI brief — competitive landscape report
- Albumin-bound docetaxel updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Albumin-bound docetaxel
What is Albumin-bound docetaxel?
Albumin-bound docetaxel is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Who makes Albumin-bound docetaxel?
Albumin-bound docetaxel is developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (see full CSPC ZhongQi Pharmaceutical Technology Co., Ltd. pipeline at /company/cspc-zhongqi-pharmaceutical-technology-co-ltd).
What development phase is Albumin-bound docetaxel in?
Albumin-bound docetaxel is in Phase 1.